Management of type 2 diabetes with thiazolidinediones: Link between β-cell preservation and durability of response

Endocrinologist

Volumn 14, Issue 5, 2004, Pages 293-299

  Bell, David S H ^a  

^a UNIVERSITY OF ALABAMA SCHOOL OF MEDICINE   (United States)

Author keywords

B cell preservation; B cell rejuvenation; Thiazolidinediones; Type 2 diabetes

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; GLUCAGON LIKE PEPTIDE 1; GLUCOSE; HEMOGLOBIN A1C; INSULIN; ROSIGLITAZONE; TROGLITAZONE;

DRUG EFFICACY; DRUG USE; GLUCOSE HOMEOSTASIS; HUMAN; INSULIN RESISTANCE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PANCREAS ISLET BETA CELL; PATHOPHYSIOLOGY; REVIEW; SYSTEMATIC REVIEW;

EID: 4544247381     PISSN: 10512144     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.ten.0000139039.06946.b2     Document Type: Review

References (57)

1. Warram JH, Martin BC, Krolewski AS, et al. Slow glucose removal rate and hyperinsulinemia precede the development of type II diabetes in the offspring of diabetic parents. Ann Intern Med. 1990;113:909-915.
2. Ford ES, Giles WH, Dietz WH. Prevalence of the metabolic syndrome among US adults: findings from the Third National Health and Nutrition Examination Survey. JAMA. 2002;287:356-359.
3. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA. 2001;285:2486-2497.
4. Pimenta W, Korytkowski M, Mitrakou A, et al. Pancreatic beta-cell dysfunction as the primary genetic lesion in NIDDM: evidence from studies in normal glucose-tolerant individuals with a first-degree NIDDM relative. JAMA. 1995;273:1855-1861.
5. Weyer C, Bogardus C, Mott DM, et al. The natural history of insulin secretory dysfunction and insulin resistance in the pathogenesis of type 2 diabetes mellitus. J Clin Invest. 1999;104:787-797.
6. DeFronzo RA, Bonadonna RC, Ferrannini E. Pathogenesis of NIDDM: a balanced overview. Diabetes Care. 1992;15:318-368.
7. Bell DSH, Ovalle F. Tissue triglyceride levels in type 2 diabetes and the role of thiazolidinediones in reversing the effects of tissue hypertriglyceridemia: review of the evidence in animals and humans. Endocr Pract. 2001;7:135-138.
8. Randle PJ, Garland PB, Hales CN, et al. The glucose fatty-acid cycle: its role in insulin sensitivity and the metabolic disturbances of diabetes mellitus. Lancet. 1963;1:785-789.
9. Itani SI, Ruderman NB, Schmieder F, et al. Lipid-induced insulin resistance in human muscle is associated with changes in diacylglycerol, protein kinase C, and IκB-α. Diabetes. 2002;51:2005-2011.
10. Petersen KF, Dufour S, Befroy D, et al. Impaired mitochondrial activity in the insulin-resistant offspring of patients with type 2 diabetes. N Engl J Med. 2004;350:664-671.
11. Lee Y, Hirose H, Ohneda M, et al. β-Cell lipotoxicity in the pathogenesis of non-insulin-dependent diabetes mellitus of obese rats: impairment in adipocyte-β cell relationships. Proc Natl Acad Sci U S A. 1994;91:10878-10882.
12. Shimabukuro M, Zhou YT, Lee Y, et al. Troglitazone lowers islet fat and restores beta cell function of Zucker diabetic fatty rats. J Biol Chem. 1998;273:3547-3550.
13. Johnson JH, Ogawa A, Chen L, et al. Underexpression of beta cell high Km glucose transporters in noninsulin-dependent diabetes [erratum appears in Science. 1990;250:1195]. Science. 1990;250:546-549.
14. Johnson JH, Ogawa A, Chen L, et al. Underexpression of beta cell high Km glucose transporters in noninsulin-dependent diabetes [erratum appears in Science. 1990;250:1195]. Science. 1990;250:546-549.
15. Milburn JL, Hirose H, Lee YH, et al. Pancreatic β-cells in obesity: evidence for induction of functional, morphologic and metabolic abnormalities by increased long chain fatty acids. J Biol Chem. 1995;270: 1295-1299.
16. Unger RH. Lipotoxicity in the pathogenesis of obesity-dependent NIDDM: genetic and clinical implications. Diabetes. 1995;44:863-870.
17. Mulder H, Holst LS, Svensson H, et al. Hormone-sensitive lipase, the rate-limiting enzyme in triglyceride hydrolysis, is expressed and active in beta-cells. Diabetes. 1999;48:228-232.
18. Winzell MS, Svensson H, Enerbäck S, et al. Pancreatic β-cell lipotoxicity induced by overexpression of hormone-sensitive lipase. Diabetes. 2003;52:2057-2065.
19. Stein DT, Stevenson BE, Chester MW, et al. The insulinotropic potency of fatty acids is influenced profoundly by their chain length and degree of saturation. J Clin Invest. 1997;100:398-403.
20. Shimabukuro M, Ohneda M, Lee Y, et al. Role of nitric oxide in obesity-induced β cell disease. J Clin Invest. 1997;100:290-295.
21. Wallace TM, Matthews DR. Poor glycaemic control in type 2 diabetes: a conspiracy of disease, suboptimal therapy and attitude. QJM. 2000; 93:369-374.
22. United Kingdom Prospective Study Group. UK Prospective Diabetes Study 16. Overview of 6 years' therapy of type 11 diabetes: a progressive disease. Diabetes. 1995;44:1249-1258.
23. Lebovitz HE. Insulin secretagogues: old and new. Diabetes Rev. 1999; 7:139-153.
24. Shimabukuro M, Koyama K, Chen G, et al. Direct antidiabetic effect of leptin through triglyceride depletion of tissues. Proc Natl Acad Sci U S A. 1997;94:4637-4641.
25. Cnop M, Grupping A, Hoorens A, et al. Endocytosis of low-density lipoprotein by human pancreatic β cells and uptake in lipid-storing vesicles, which increase with age. Am J Pathol. 2000; 156:237-244.
26. Butler AE, Janson J, Bonner-Weir S, et al. β-cell deficit and increased β-cell apoptosis in humans with type 2 diabetes. Diabetes. 2003;52:102-110.
27. Gremlich S, Bonny C, Waeber G, et al. Fatty acids decrease IDX-1 expression in rat pancreatic islets and reduce GLUT2, glucokinase, insulin and somatostatin levels. J Biol Chem. 1997;272:30261-30269.
28. Corbett JA, McDaniel ML. Intra-islet release of interleukin 1 inhibits β cell function by inducing β cell expression of inducible nitric oxide synthase. J Exp Med. 1995;181:559-568.
29. Shimabukuro M, Ohneda M, Lee Y, et al. Role of nitric oxide in obesity-induced β cell disease. J Clin Invest. 1997;100:290-295.
30. Zhou Y-T, Graburn P, Karim A, et al. Lipotoxic heart disease in obese rats: implications for human obesity. Proc Natl Acad Sci U S A. 2000;97:1784-1789.
31. Lister CA, Moore GBT, Piercy V, et al. Rosiglitazone, but not metformin or glibenclamide, improves glycaemic control and increases islet insulin content [Abstract]. Diabetologia. 1999;42(suppl 1):A150.
32. Finegood DT, McArthur MD, Kojwang D, et al. β Cell mass dynamics in Zucker diabetic fatty rats: rosiglitazone prevents the rise in net cell death. Diabetes. 2001;50:1021-1029.
33. Shen Z, Hull R, Kodama K, et al. Long term rosiglitazone and metformin treatment reduce the severity of islet amyloid but do not prevent its formation [Abstract]. Diabetes. 2003;52(suppl 1):A338-339.
34. Fonseca V, Rosenstock J, Patwardhan R, et al. Effect of metformin and rosiglitazone combination therapy in patients with type 2 diabetes mellitus: a randomized controlled trial. JAMA. 2000;283:1695-1702.
35. Rosenstock J, Porter LE, Heise MA, et al. Type 2 diabetes in the elderly: reaching durable glycaemic goals with combination sulphonlyurea and rosiglitazone. Presented at the International Diabetes Federation Meeting; August 24-29, 2003; Paris, France.
36. Porter LE, Freed MI, Jones NP, et al. Rosiglitazone improves β-cell function as measured by proinsulin/insulin ratio in patients with type 2 diabetes [Abstract]. Diabetes. 2000;49(suppl 1):A122.
37. Bell DS.: β-cell rejuvenation with thiazolidinediones. Am J Med. 2003; 115(suppl 8A):20S-23S.
38. Ovalle F, Bell DSH. Clinical evidence of thiazolidinedione-induced improvement of pancreatic β-cell function in patients with type 2 diabetes mellitus. Diabetes Obes Metab. 2002;4:56-59.
39. Ovalle F, Bell DSH. Effect of rosiglitazone versus insulin on the pancreatic beta cell function of subjects with type 2 diabetes mellitus [Abstract]. Diabetes. 2003;52(suppl 1):A130.
40. Raskin P, Rappaport EB, Cole ST, et al. Rosiglitazone short-term monotherapy lowers fasting and post-prandial glucose in patients with type 11 diabetes. Diabetologia. 2000;43:278-284.
41. Triplitt C, Cersosimo E, Miyazaki Y, et al. Combination metformin and rosiglitazone therapy: mechanism of glucose lowering in newly diagnosed type 2 diabetes [Abstract]. Diabetes. 2003;52(suppl 1):A144.
42. Polyzogopoulou EV, Kalfarentzos F, Vagenakis AG, et al. Restoration of euglycemia and normal acute insulin response to glucose in obese subjects with type 2 diabetes following bariatric surgery. Diabetes. 2003;52:1098-1103.
43. Marceau P, Hould FS, Lebel S, et al. Malabsorptive obesity surgery. Surg Clin North Am. 2001;81:1113-1127.
44. Ovalle F, Bell DSH. Triple oral antidiabetic therapy in type 2 diabetes mellitus. Endocr Pract. 1998;4:146-147.
45. Bell DSH, Ovalle F, Shadmany S. Conversion from troglitazone to rosiglitazone [Letter]. Endocr Pract. 2001;7:326.
46. Bell DSH, Ovalle F. Long-term efficacy of triple oral therapy for type 2 diabetes mellitus. Endocr Pract. 2002;8:271-275.
47. Buchanan TA, Xiang AH, Peters RK, et al. Preservation of pancreatic β-cell function and prevention of type 2 diabetes by pharmacological treatment of insulin resistance in high-risk Hispanic women. Diabetes. 2002;51:2796-2803.
48. The Diabetes Prevention Program Research Group. Prevention of type 2 diabetes with troglitazone in the Diabetes Prevention Program (DPP) [Abstract]. Diabetes. 2003;52(suppl 1):A58-59.
49. Deacon CF, Holst JJ, Carr RD. Glucagon-like peptide-1: a basis for new approaches to the management of diabetes. Drugs Today. 1999;35:159-170.
50. Ahren B, Larsson H, Holst JJ. Reduced gastric inhibitory polypeptide but normal glucagon-like peptide 1 response to oral glucose in post menopausal women with impaired glucose tolerance. Eur J Endocrinol. 1997;137:127-131.
51. Vaag AA, Holst J, Volund A, et al. Gut incretin hormones in identical twins discordant for non-insulin-dependent diabetes mellitus (NIDDM): evidence for decreased glucagon-like peptide 1 secretion during oral glucose ingestion in NIDDM twins. Eur J Endocrinol. 1996;135:425-432.
52. Vilsboll T, Krarup T, Deacon CF, et al. Reduced postprandial concentrations of intact biologically active glucagon-like peptide 1 in type 2 diabetic patients. Diabetes. 2001;50:609-613.
53. Buteau J, Roduit R, Susini S, et al. Glucagon-like peptide-1 promotes DNA synthesis, activates phosphatidylinositol 3-kinase and increases transcription factor pancreatic and duodenal homeobox gene 1 (PDX-1) DNA binding activity in beta (INS-1) cells. Diabetologia. 1999;42:856-864.
54. Kang G, Holz GG. Amplification of exocytosis by Ca2+ induced Ca2+ release in INS-1 pancreatic beta cells. J Physiol. 2003;546:175-189.
55. Drucker DJ. Glucagon-like peptides: regulators of cell proliferation, differentiation, and apoptosis. Mol Endocrinol. 2003;17:161-171.
56. Del Zotto H, Massa L, Rafaeloff R, et al. Possible relationship between changes in islet neogenesis and islet neogenesis-associated protein-positive cell mass induced by sucrose administration in normal hamsters. J Endocrinol. 2000;165:725-733.
57. Taylor-Fishwick DA, Rittman S, Kendall H, et al. Cloning genomic INGAP: a Reg-related family member with distinct transcriptional regulation sites. Biochem Biophys Acta. 2003;1638:83-89.